Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

Kara et al., NCT04411433, NCT04411433, Jun 2021
1,008 patient favipiravir early treatment RCT with results not reported over 5 years after completion.
Potential risks of favipiravir include kidney injury1-3, liver injury2-5, cardiovascular events5,6, pulmonary toxicity6,7, and mutagenicity, carcinogenicity, teratogenicity, embryotoxicity, and the creation of dangerous variants8-14.
2 favipiravir RCTs have results missing long after expected15,16
The trials report total actual enrollment of 1,128 patients.
Study covers favipiravir and HCQ.
Kara et al., 1 Jun 2021, Randomized Controlled Trial, Turkey, peer-reviewed, trial NCT04411433 (history). Contact: ateskara@hacettepe.edu.tr.